Roivant Sciences (ROIV)

Roivant’s commercial product is VTAMA, or tapinarof, a topical therapy approved for plaque psoriasis in adults. The medicine gives the company direct exposure to the dermatology market and provides a commercial foundation alongside its development pipeline. The broader strategy is to identify drug candidates with meaningful clinical rationale, advance them through trials, and either commercialize them directly or create value through partnerships and strategic transactions.

The company’s pipeline includes batoclimab and IMVT-1402, which target FcRn and are being developed for autoimmune conditions, as well as brepocitinib, namilumab, and other candidates at various stages of clinical development. These programs address immune-mediated diseases where existing therapies may not work for all patients or may carry limitations in safety, convenience, or durability of response.

Roivant also incubates discovery-stage biotechnology companies and health technology startups that complement its drug development activities. This gives the business a hybrid profile: part commercial biopharma company, part life sciences platform. For investors, Roivant is defined by the performance of VTAMA, the clinical and regulatory progress of its pipeline, and management’s ability to allocate capital across a broad set of therapeutic opportunities.